"10.1371_journal.pone.0044877","plos one","2012-10-10T00:00:00Z","Ramon Casanova; Fang-Chi Hsu; Mark A. Espeland, for the Alzheimer's Disease Neuroimaging Initiative","Department of Biostatistical Sciences, Wake Forest School of Medicine, North Carolina, United States of America","Â¶ Membership of the Alzheimers Disease Neuroimaging Initiative is provided in the Acknowledgments.","ADNI, one of the funders of this study, is partly funded through generous contributions from the following: Abbott; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. .","2012","10","Ramon Casanova","RC",3,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
